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ABNORMAL levels of pulmonary eicosanoids have
been reported in infants with persistent pulmon-
ary hypertension (PPH) and congenital diaphrag-
matic hernia (CDH). We hypothesized that a
dysbalance of vasoconstrictive and vasodilatory
eicosanoids is involved in PPH in CDH patients.
The levels of several eicosanoids in lung homo-
genates and in bronchoalveolar lavage ￿ uid of
controls and rats with CDH were measured after
caesarean section or spontaneous birth. In con-
trols the concentration of the stable metabolite
of prostacyclin (6-keto-PGF1a), thromboxane A2
(TxB2), prostaglandin E2 (PGE2), and leukotriene
B4 (LTB4) decreased after spontaneous birth. CDH
pups showed respiratory insuf￿ ciency directly
after birth. Their lungs had higher levels of 6-
keto-PGF1a, re￿ ecting the pulmonary vasodilator
prostacyclin (PGI2), than those of controls. We
conclude that in CDH abnormal lung eicosanoid
levels are present perinatally. The elevated levels
of 6-keto-PGF1a in CDH may re￿ ect a compensa-
tion mechanism for increased vascular resistance.
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Introduction
Eicosanoids are arachidonic acid metabolites
which are produced in different tissues in
human and animal species.1 They have been
studied extensively in relation to the perinatal
pulmonary circulation, and have been impli-
cated in several physiologic and pathologic
conditions such as persistent pulmonary hyper-
tension (PPH).2 7
Prostacyclin (PGI2), prostaglandin E2 (PGE2),
and thromboxane A2 (TxA2) are all generated
via the cyclooxygenase pathway; the latter has
a pulmonary vasoconstricting activity, whereas
the other two are pulmonary vasodilators.6
Increased circulating levels of PGE2 may con-
tribute to the pathogenesis of patent ductus
arteriosus.8 Leukotrienes, which are formed by
the 5-lipoxygenase pathway, may have a key
function in maintaining the elevated pulmonary
vascular resistance in the fetus,6,9 although this
could not be con￿rmed in other studies.7,10
Children with congenital diaphragmatic her-
nia (CDH) have abnormal morphological devel-
opment of lungs and intrapulmonary blood
vessels.11,12 The high neonatal mortality and
morbidity is ascribed to the extent of lung
hypoplasia and PPH.13 Increased levels of leuko-
trienes, and of metabolites of PGI2 and TxA2
have been reported in plasma and in broncho-
alveolar lavage (BAL) ￿uid of both PPHpatients
without CDHand children with CDH. 14 21
We hypothesized that the pulmonary vascular
abnormalities in CDHcause abnormal transition
of the pulmonary circulation at birth, associated
with a dysbalance of vasoconstrictive and vaso-
dilatory eicosanoids. Therefore, we studied the
content of different eicosanoids—metabolites
from the cyclooxygenase and one from the
lipoxygenase pathway—in lung homogenates
and in BAL ￿uid of perinatal rats with CDH.22
The pulmonary vascular abnormalities in these
rat pups strongly resemble those of children
with CDH.23
Materials and Methods
Animal model
Female Sprague-Dawley rats (Harlan Olac, UK)
were mated during 1 h (day 0 of gestation).
Nine of 18 pregnant rats received 100 mg of
2,4-dichloro-phenyl-p-nitrophenylether (Nitro-
fen: Rohm Haas Company, Philadelphia, PA) in
1 ml of olive oil orogastrically under light ether
anaesthesia on day 10 of gestation;22 the remain-
ing nine rats provided control pups. Nitrofen
induces a large left-sided diaphragmatic defect
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offspring using this regimen.22 Food and water
were supplied ad libitum during the whole
period of pregnancy. Nine pregnant dams were
anaesthetized by inhalation of diethylether and
a caesarean section was performed on day 22
(nitrofen-exposed litters n 5; control litters
n 4). While they were kept in the membranes
to prevent any breathing, the fetuses died after
cervical intersection with a needle, and were
weighed. Only rat pups that could be processed
within the ￿rst 30 min of anaesthesia were
included. In the remaining litters (nitrofen-
exposed n 4, and controls n 5) sponta-
neous birth on day 22± 23 was awaited; within
5± 10 min after birth they were killed as de-
scribed above, and weighed. The presence of a
diaphragmatic defect in all nitrofen-exposed rat
pups was revealed by autopsy. To obtain a
homogeneous group only nitrofen-exposed rat
pups with left-sided or bilateral diaphragmatic
defects with concomitant severe lung hypopla-
sia were included, and nitrofen-exposed pups
with small right-sided defects or without CDH
were excluded. Thus four different groups were
studied: CDH rat pups after caesarean section
or born spontaneously, and control pups after
caesarean section or born spontaneously. Either
BAL procedure or dissection of the lungs for
preparation of homogenates was then per-
formed.
Lung homogenates
The lungs were removed, stripped of non-
pulmonary tissue, separated, weighed, frozen in
liquid N2, and stored at 708 C until further
processed. They they were homogenized in
1 ml in Krebs-solution, and centrifuged at
2500 g. The content of eicosanoids and protein
was measured in the supernatant. Ten samples
were obtained in CDH pups after caesarean
section and four in spontaneously born pups. In
controls the numbers were n 11 and n 23,
respectively.
BAL procedure
After opening of the abdominal cavity and
assessment of the diaphragmatic defect in the
nitrofen-exposed pups, the thorax was opened,
and a tracheotomy was performed. A poly-
ethylene catheter (Portex, UK; outer diameter
0.61 mm or 1.0 mm, inner diameter 0.28 or
0.5 mm, for CDH pups and controls respec-
tively) was inserted into the trachea and ligated.
A 1 ml-syringe with NaCl 0.9% , heated to 378 C,
was connected to the catheter, and the lungs
were washed as previously described.24 In CDH
pups the lungs were washed with seven to 10
times 0.05 to 0.1 ml. Lungs from control pups
were washed four times with 0.25 to 0.45 ml,
until 1 ml of ￿uid had been recovered. Samples
that were visibly contaminated with blood were
excluded. Ten samples were obtained in each
CDH group, and 13 samples in each control
group. The BAL ￿uid was directly frozen in
liquid N2 and stored at 708 Cuntil assay.
Measurement of eicosanoids and
total protein
The following eicosanoids were measured by
radioimmunoassay: 6-keto-PGF1a (the stable me-
tabolite of prostacyclin), PGE2, TxB2 (the stable
metabolite of TxA2), all three generated by the
cyclooxygenase pathway, and leukotriene B4
(LTB4), a lipoxygenase-derived metabolite of
arachidonic acid. All assays were performed as
described in detail previously.25 Total protein
was measured by ELISA at 595 nm using a
commercially available protein reagent and pro-
tein standard (Instruchemie B.V ., Hilversum, the
Netherlands).
Data analysis
All eicosanoid levels are expressed as pg/mg
protein (mean SEM), unless stated otherwise.
Differences between groups were tested by
Student’s t-test or by the non-parametric Mann±
Whitney test if appropriate. Statistical signi￿-
cance was assumed at 5%level.
Results
All spontaneously born control pups had a
regular respiration rate and were pink within
minutes after birth. Respiratory insuf￿ciency
with gasping and cyanosis was observed in rat
pups with CDH, but not in controls, directly
after birth.
The lung weights in spontaneously born
control pups were signi￿cantly lower than
those in controls delivered by caesarean section
(Table 1; P , 0.001). This was not the case in
the CDHpups: the lung weights were similar in
both groups (Table 1). Control lungs were
signi￿cantly heavier than lungs in CDH (P ,
0.001).
Results in lung homogenates
First, data from the left and the right lungs in all
groups were analysed separately to determine
whether there were consistent differences in
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contralateral lungs in CDH (data not shown).
This was not the case, however, and data from
both lungs were therefore pooled.
In CDHpups protein per mg wet lung weight
was higher than in controls: 28.8 0.8 mg and
27.5 1.1 mg after caesarean section and spon-
taneous delivery in CDH, respectively, and 13.5
0.1 mg and 18.5 0.6 mg in controls, respec-
tively (P , 0.001). In controls the protein con-
tent per mg lung weight was signi￿cantly lower
in pups who were delivered by caesarean
section than in spontaneously born pups
(P , 0.001), but this was not true for the total
protein content in both lungs (2020 9 mg after
caesarean section and 2060 24 mg after spon-
taneous birth). In all control pups the total
amount of protein was higher than in CDH
pups, whose lungs contained 1760 12 mg and
1710 8 mg protein in the respective groups
(P , 0.001).
The eicosanoid concentrations per mg protein
measured in the lung homogenates are shown
in Fig. 1. In controls the concentrations of all
eicosanoids per mg protein (Fig. 1A± D) and the
total amount of eicosanoids (Table 1) were
signi￿cantly lower in spontaneously born pups,
compared with those in the caesarean section
group. In CDHpups the eicosanoid levels were
not affected by the delivery mode; this was also
the case for the eicosanoid content per mg lung
weight (data not shown).
The levels of 6-keto-PGF1a per mg protein
(Fig. 1A; P , 0.001) and the total amount of 6-
keto-PGF1a (Table 1; P , 0.001) were signi￿-
cantly higher in CDH than in controls. In
addition, the ratio of 6-keto-PGF1a to TxB2 was
calculated for each group; in the caesarean
section group it was 0.38 0.03 and
0.16 0.01 for CDH and controls, respectively
(P , 0.001), and for spontaneously born rat
pups 0.39 0.02 and 0.16 0.01, respectively
(P , 0.001).
Controls born by caesarean section had high-
er total TxB2 than CDH pups (T able 1; P
0.006) and a tendency towards higher TxB2 per
mg protein (Fig. 1B; P 0.08). No such differ-
ences for TxB2 were observed in the sponta-
neously born rat pups. PGE2 per mg protein was
signi￿cantly higher in control pups delivered by
caesarean section than in CDH pups (Fig. 1C;
P 0.003). The total amounts of PGE2 were
higher in controls than in CDH pups, irrespec-
tive of the delivery mode (Table 1). The
concentration of LTB4 per mg protein (Fig. 1D)
and the total amount of LTB4 (Table 1) were
signi￿cantly higher in controls than in CDH
pups after caesarean section (P , 0.001),
whereas both groups showed similar LTB4 levels
after spontaneous delivery.
Eicosanoids in BAL ¯ uid
In BAL￿uid a wide range of eicosanoid concen-
trations was observed. In controls the concen-
trations per ml BAL ￿uid of 6-keto-PGF1a, TxB2,
and LTB4 were higher after spontaneous birth
than after caesarean section (Table 2; P 0.01,
0.06, and , 0.001, respectively). However, after
correction for dilution, with total protein as
marker, only LTB4 was signi￿cantly higher after
spontaneous birth (T able 2; P 0.02). CDH
pups showed higher uncorrected concentration
levels of TxB2 and LTB4 in spontaneously
born rats compared with pups delivered by
caesarean section (Table 2; P 0.04 and 0.05,
respectively). The same volumes in CDH pups
were so small that the protein concentration
could only be measured in eight samples (n 4
per group).
Table 1. Lung weights and total amount of eicosanoids in lung homogenates of
controls and CDH pups after delivery by caesarean section or after spontaneous birth
Caesarean section Spontaneous birth
Lung weight (mg) Control 149 2 115 4b
CDH 62 2a 62 3a
6-keto-PGF1a (pg) Control 4340 210 3260 160b
CDH 7830 320a 7670 270a
TxB2 (pg) Control 27620 1600 21560 850b
CDH 21070 1320a 19970 880
PGE2 (pg) Control 42110 2210 30410 1450b
CDH 27750 2050a 24690 1630a
LTB4 (pg) Control 3410 180 2950 130b
CDH 2160 150a 2610 350
All data are expressed as mean SEM. The numbers per group are: n 11 and n 23 for the
controls delivered by caesarean section and by spontaneous birth, respectively; n 10 and n 4
for the respective CDH groups.
aSigni® cantly different from control, same delivery mode; P , 0.05.
bSigni® cantly different from caesarean section, same group; P , 0.05.
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Lung eicosanoids in CDHThe ratio of 6-keto-PGF1a and TxB2 in BAL
￿uid was signi￿cantly higher in CDHpups than
in controls who were delivered by caesarean
section (7.93 2.95 and 2.22 0.5, respec-
tively; P 0.02). A similar tendency was ob-
served for the spontaneously born rat pups
(3.63 1.13 for CDH, and 1.48 0.32 for con-
trols; P 0.06).
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FIG. 1. Concentration of 6-keto-PGF1a (1A), TxB2 (1B), PGE2 (1C), and LTB4 (1D) per mg protein in lung homogenates of rat
pups with CDH and controls delivered by caesarean section (squares) or spontaneously born pups (triangles). Median is
indicated for each group. Signi® cantly different from controls; similar mode of delivery; P , 0.01. Signi® cantly different
from controls after spontaneous birth; P , 0.02.
Table 2. Eicosanoids in BAL ¯ uid of controls and CDH pups after delivery by
caesarean section or after spontaneous birth
Caesarean section Spontaneous birth
6-keto-PGF1a (pg/ml) Control 171 (64± 303) 278 (102± 743)a
CDH 207 (110± 521) 243 (172± 617)
6-keto-PGF1a (pg/mg protein) Control 1.72 (0.58± 14.8) 1.43 (1.06± 4.04)
CDH 5.53 (1.88± 38.9) 1.81 (1.12± 3.52)
TxB2 (pg/ml) Control 100 (23± 372) 182 (78± 496)
CDH 65 (6± 140) 96 (19± 305)a
TxB2 (pg/mg protein) Control 1.19 (0.47± 5.33) 1.18 (0.3± 2.75)
CDH 1.62 (0.16± 6.72) 0.69 (0.43± 2.5)
LTB4 (pg/ml) Control 15 (5± 105) 162 (25± 661)a
CDH 42 (14± 194) 100 (51± 200)a,b
LTB4 (pg/mg protein) Control 0.24 (0.08± 6.9) 0.92 (0.12± 2.57)a
CDH 0.23 (0.19± 2.0) 0.87 (0.38± 0.99)
All values are expressed as median (range). Data shown per ml BAL ¯ uid are n 10 for each
CDH group and n 13 per control group. Data shown per mg protein are n 4 for each CDH
group, n 13 for controls delivered by caesarean section, and n 10 for spontaneously born
controls.
aSigni® cantly different from caesarean section in the same group; P , 0.05.
bSigni® cantly different from spontaneously born CDH pups; P , 0.05.
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In the present study higher levels of
6-keto-PGF1a, the stable metabolite of the pul-
monary vasodilator PGI2, were found in the
lungs of CDH pups than in those of controls,
irrespective of the mode of delivery. Lungs of
CDH pups had similar or lower levels of TxB2,
PGE2, and LTB4 than control pups. All eico-
sanoids studied were higher in the lungs of
control pups delivered by caesarean section
than in those born spontaneously; this was not
the case in CDHpups.
The lower lung weights in spontaneously
born controls compared with those delivered
by caesarean section probably indicate that lung
￿uid was absorbed to a large extent during the
￿rst adequate breaths. The gasping, irregular
breathing movement in the spontaneously born
CDH pups have been insuf￿cient to overcome
the pressure that is needed to initiate lung
expansion and to provide adequate lung aera-
tion and absorption of lung ￿uid,26,27 thus
explaining the similar lung weights in both
CDHgroups.
We studied the eicosanoid concentration both
in lung homogenates and in BAL ￿uid to
determine whether the concentration in BAL
￿uid adequately re￿ects the situation in the lung
tissue. We found widely varying eicosanoid
concentrations in BAL ￿uid of the neonatal rat
pups. After correction for protein, only the
concentration of 6-keto-PGF1a in control pups
showed comparable results between BAL ￿uid
and lung homogenates. The concentration of
TxB2 was generally 10 times higher in lung
homogenates than in BAL ￿uid, which suggests
that thromboxane is mainly present in the
pulmonary vasculature and not into the air-
spaces. The same may be true for the concen-
tration of LTB4 during intrauterine life. Our data
support earlier observations that the eicosanoid
content in the pulmonary vasculature is more
adequately re￿ected in tissue homogenates than
in BAL￿uid.7 However, the ratio of 6-keto-PGF1a
and TxB2 was signi￿cantly higher in lung
homogenates and in BAL ￿uid of CDH pups
than in that of controls, suggesting that this
parameter in BAL ￿uid re￿ects the values in
lung tissue. A high ratio of 6-keto-PGF1a and
TxB2 was also found in BAL ￿uid of two CDH
patients with evidence of PPH (unpublished
data).
During normal transition from intrauterine to
extrauterine life, the pulmonary vascular resis-
tance rapidly declines within the ￿rst 30 s, and
declines more slowly over the next 10± 20 min.2
The ￿rst phase occurs irrespective of prosta-
glandin synthase blockade by indomethacin,2
but several studies in lambs and goats indicate
that a transient prostacyclin production in the
lungs, which is stimulated by tissue stress
during establishment of gaseous ventilation and
rhythmic ventilation,4 is important to sustain
further pulmonary vasodilatation within the ￿rst
hours after birth.2 4,7
The lower levels of all eicosanoids in lung
tissue of normal controls compared with CDH
pups following spontaneous birth in this study
seem to contradict the earlier ￿ndings in new-
born lambs and goats.2 4,7 Perhaps the de-
scribed loss of prostacyclin from the lungs
shortly before birth3 continued immediately
after birth, and the rat pups died before the
prostacyclin concentration began to increase.
However, the CDH pups could not survive
much longer without arti￿cial ventilation and
supplemental oxygen.
Persistent pulmonary hypertension is a ser-
ious problem in neonatology which largely
contributes to the neonatal mortality and
morbidity in isolated cases of PPH,28 and in
children with CDH.13 Improvement of oxygena-
tion parameters in some children with PPHhas
been reported after intravenous or inhaled
administration of prostacyclin,29,30 although
other patients seem irresponsive to vasodilator
therapy like prostacyclin29 or inhaled nitric
oxide.28
Increased levels of 6-keto-PGF1a, TxB2, PGE2,
and leukotrienes have been reported in plasma
and in bronchoalveolar lavage ￿uid of PPH
patients14,17,19,21 and in plasma of CDHpatients
with PPH.15,16,21 A decrease in all eicosanoid
levels was observed during clinical improve-
ment, especially in patients who were being
treated with extracorporeal membrane oxygen-
ation.16,21 It has been suggested that LTC4, LTD 4
and TxB2 have a pulmonary vasoconstricting
activity, whereas 6-keto-PGF1a opposes the hy-
poxic vasoconstriction.31
In a fetal lamb model of chronic intrauterine
pulmonary hypertension32 increased pulmonary
levels of 6-keto-PGF1a and TxB2 were detected
shortly before, and 2 h after birth.7 Our study
did not reveal signi￿cant differences in eico-
sanoid content in the lungs of the CDH rats
during transition from intrauterine to extrauter-
ine life; this may be due to the short period of
survival after birth and the lack of adequate
respiratory movements.
We found increased levels of 6-keto-PGF1a per
mg protein, and decreased levels of PGE2 and
LTB4 in lung tissue of CDH pups in the
caesarean section group. Surprisingly, the con-
centration of TxB2 per mg protein was similar in
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certain total amount of eicosanoids is important
to exert a local effect, and we therefore deter-
mined the total eicosanoid content in both
lungs of CDH and control pups. The results
were similar to the data that were corrected for
protein. The increased ratio of 6-keto-PGF1a and
TxB2 in CDHpups compared with control pups
con￿rms the presence of a dysbalance in vaso-
active mediators, which is in favour of the
pulmonary vasodilator. It has been suggested
that prostaglandin generation in the pulmonary
vasculature may reduce the pulmonary vascular
pressure response to hypoxia.31 Cott and co-
workers33 showed in adult rats that alveolar
type II cells are capable of producing high
levels of 6-keto-PGF1a and PGE2 in vitro,
whereas TxB2 and LTB4 are mainly produced by
alveolar macrophages. Brandsma and co-
workers34 reported more type II cells that
showed retarded differentiation in CDH lungs.
The relatively higher number of type II cells
may be responsible for the increased 6-keto-
PGF1a content in the CDHlungs.
In conclusion, the present study shows differ-
ent eicosanoid pro￿les in lungs of perinatal rats
with and without CDH. The most striking ￿nd-
ings are the elevated concentration of
6-keto-PGF1a, and the increased ratio of 6-keto-
PGF1a and TxB2 in CDHlungs. This is the ￿rst
study of lung eicosanoids in perinatal animals
with abnormal lung development. From the
present data it is not clear whether the balance
which is in favour of 6-keto-PGF1a, the stable
metabolite of the pulmonary vasodilator PGI2,
compensates for an increased pulmonary vascu-
lar tone or that it re￿ects delayed cell differen-
tiation in CDH. Our ￿ndings give reason to
assume that lungs of CDH patients with PPH
already contain increased levels of prostacyclin
at birth and that the administration of exogen-
ous vasodilators will not be helpful to decrease
the pulmonary vascular resistance in those
patients.
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